Abstract: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.

Abstract: The present application provides methods for the treatment of cancer, comprising administering substantially non-anticoagulant 2-O, 3-O desulfated heparin to patients suffering from cancer that is, or can become resistant to, cancer treatment, such as chemotherapy, targeted cancer therapy, or radiation therapy. The compositions can be administered to sensitize, or to reverse resistance to, cancer treatment, and can be administered alone or in combination with cancer treatment to subjects with solid tumors including, but not limited to, pancreatic, breast, renal, colorectal, gastric, or esophageal cancer, and subjects with hematologic malignancies, including but not limited to leukemia and lymphoma.

Abstract: A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin-and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.

Abstract: A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin- and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.